Since February of this year Danish Ramcon A/S offers Anagnostics’ drugs of abuse testing and pharmacogenetics solutions as distribution partner.
During the course of the year, further products, especially relating to severe infection testing will follow.
Establishing the innovative products in the Northern European Countries as well as competent and first class customer support are common goals of the partners.
“The decision to partner with Ramcon simply made sense, since Ramcon already specializes in tests and systems for in vitro diagnostics and life sciences with a loyal and broad customer base. Ramcon focuses on first class end-user service and support. Therefore both organizations perfectly fit together”, summarizes Markus Jaquemar, CMO Anagnostics Bioanalysis GmbH.
Jesper Hardt, CEO of Ramcon A/S, is looking forward to a successful partnership: “We can see a clear trend towards multiplex testing. Anagnostics perfectly responds to these market needs with the hyborg system and its testing menu. The fast and efficient response to actual drug consumption will secure access to drug therapy institutions. The efficient and highly sensitive pharmacogenetics test will benefit small or mid-sized pathological entities.”
Multiplex Diagnostics with Focus on Drugs of Abuse Screening, Pharmacogenetics (Oncology) and Serve Infection Testing Anagnostics Bioanalysis with its headquarters in St. Valentin (Austria) is specialized in developing systems, devices and tests in drugs of abuse screening, pharmacogenetics (oncology) and tests for diagnosing severe infections.
With the unique ability to perform protein as well as DNA based assays the hyborg system offers a testing platform meeting needs of personalized medicine and integrated diagnostics.
Anagnostics was established in 2005 by Bernhard Ronacher, a molecular genetics scientist. A cylindrical microarray - the hybcell - is the core of the patented multiplex technology.
Combined with the hyborg analysis system multi-parameter assays are performed in a fully automated manner.